World Health Organization. (2019). International Classification of Diseases for Mortality and Morbidity Statistics (ICD-10). Geneva: WHO.
[2]
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424.
[3]
Amant, F., Mirza, M. R., Koskas, M., & Creutzberg, C. L. (2018). Cancer of the corpus uteri. International Journal of Gynecology & Obstetrics, 143(S2), 37-50.
[4]
Koh, W. J., Abu-Rustum, N. R., Bean, S., Bradley, K., Camposeco, S. M., Chon, H. S., ... & Scavone, J. L. (2019). Uterine Neoplasms, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17(2), 153-170.
[5]
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., González-Martín, A., Ledermann, J., ... & Sessa, C. (2016). ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Annals of Oncology, 27(1), 16-41.
[6]
Burke, W. M., Orr, J., Leitao, M., Salmang, E., Nolte, S., Bohlke, M., ... & Teng, N. (2014). Endometrial cancer: A review and current management strategies. Gynecologic Oncology, 134(2), 385-392.
[7]
Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., & Darai, E. (2016). Endometrial cancer. The Lancet, 387(10023), 1094-1108.
[8]
National Cancer Institute. (2021). Endometrial Cancer Treatment (PDQ®)–Health Professional Version. Bethesda, MD: NCI.
[9]
Crosbie, E. J., Zwahlen, M., Kitchener, H. C., Egger, M., & Renehan, A. G. (2010). Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiology Biomarkers & Prevention, 19(12), 3119-3130.
[10]
Uterine Cancer - StatPearls - NCBI Bookshelf. (2021). Bethesda, MD: National Center for Biotechnology Information.